Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT00699062 Completed - Asthma Clinical Trials

Effect of Montelukast on the Airway Remodeling

Start date: January 2010
Phase: Phase 4
Study type: Interventional

The distal lung contributes to asthmatic airway remodeling which is observed from early onset of the disease. Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory effect. The cysteinyl leukotriene antagonist Montelukast has been in vivo shown to significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial fibrosis in sensitized mice. This study aims to evaluate if Montelukast could reverse airway remodeling in asthma patients by a non-invasive approach-HRCT.

NCT ID: NCT00697801 Completed - Asthma Clinical Trials

Study of MAP0010 in Asthmatic Children and Adolescents

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.

NCT ID: NCT00697697 Terminated - Asthma Clinical Trials

A Study of 2 Doses of MAP0010 in Asthmatic Children

Start date: April 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.

NCT ID: NCT00695604 Withdrawn - Asthma Clinical Trials

Repeated High-dose Inhaled Corticosteroids for Asthma

ReHICS
Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to to compare the effects of high-dose Inhaled Corticosteroids (ICS) vs. placebo in adults with chronic stable asthma.

NCT ID: NCT00692978 Completed - Healthy Clinical Trials

Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate

Start date: August 2008
Phase: Phase 4
Study type: Interventional

Asthma is most effectively treated by delivering inhaled drugs from an inhaler (puffer) directly into the lungs. Inhaled steroids are used in asthmatic patients to dampen down lung inflammation, which unchecked, can often lead to patient symptoms. Inhalers deliver a mist containing particles of lots of different sizes (like hairsprays). Medical puffers used by patients produce a 'coarse' mist of drug particles, which have the potential for side effects, as different sized particles will reach different parts of the airways and include; the mouth, the throat, the windpipe, and the bloodstream (all places we do not want the inhaled drug to go - and can give rise to important side effects)and, the lungs (where we do want the drug to 'deposit'). Our aim in this study is to test an inhaled steroid by giving it to subjects as a 'fine' mist containing drug particles of nearly all one size using a research nebuliser (a Spinning Top Aerosol Generator). We shall use small, intermediate and large drug particle mists. We aim to find out how much of the drug goes to the blood stream for each particle mist and compare it with the standard puffers used in routine clinical practice. We hope this study will provide information to the rationale that by improving the efficiency of drug delivery (by changing drug particle size) one may improve inhaled drug delivery and ultimately, clinical patient benefit. Healthy volunteers and asthmatic patients will be recruited at the Royal Brompton Hospital London. The study is funded by GlaxoSmithKline, Research & Development, U.K.

NCT ID: NCT00691951 Completed - Asthma Clinical Trials

Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects

D5890L00013
Start date: n/a
Phase: Phase 3
Study type: Interventional

A reduced response to inhaled corticosteroids (ICS) has been reported in smoking compared to non-smoking asthmatic patients. However, the comparative response to other currently prescribed medications such as combination therapy of long-acting beta agonists and ICS remain to be further evaluated. No significant differences were found between our group of subjects in regard to changes in asthma control pulmonary function and airway inflammation following budesonide or the association of budesonide with formoterol for a period of 2 months. This should be further explored in larger groups of subjects.

NCT ID: NCT00691873 Completed - Asthma Clinical Trials

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

Start date: May 2006
Phase: Phase 4
Study type: Interventional

In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab (administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).

NCT ID: NCT00689806 Withdrawn - Clinical trials for Severe Persistent Asthma

Evaluation of Lovastatin in Severe Persistent Asthma

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

This study has two purposes: 1. to determine whether lovastatin, a commonly used medication to lower cholesterol in the blood, can produce beneficial changes in airway inflammation and in the airway smooth muscle 2. to examine whether lovastatin will have favorable changes in asthma symptoms of patients with moderate or severe asthma.

NCT ID: NCT00688792 Not yet recruiting - Asthma Clinical Trials

Maternal Variables Associated With Adherence in Children With Asthma

asthma
Start date: July 2008
Phase: N/A
Study type: Observational

A questionnaire will be used in order to find out the reasons for poor adherence for long-term treatment in children with asthma. The hypotheses is maternal factors including the knowledge that asthma is a chronic disease and fear to administer inhaled steroids are major obstacles for appropriate adherence.

NCT ID: NCT00688467 Completed - Asthma Clinical Trials

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Start date: June 1, 2008
Phase: Phase 2
Study type: Interventional

Evaluation of treatment in participants with mild asthma.